Metaprotereol Sulfate Inhalation Solution, 5%
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
bronchial asthma and reversible bronchospasm
General Information
Metaprotereol Sulfate Inhalation Solution, 5% has been approved
for the treatment of bronchial asthma and reversible bronchospasm.
The product is also indicated for the treatment of acute asthmatic
attacks in children over the age of six. Metaprotereol Sulfate
Inhalation Solution, 5% was found to be therapeutically
bioequivalent to the listed drug, Alupentr Inhalation Solution, 5%
marketed by Boehringer Ingelheim Pharmaceuticals, Inc.